Therapeutic area
Rare disease
Rare and orphan-disease programs, where a single trial can define a company and non-dilutive grant funding runs deep.
680 pre-ticker companies classified in rare disease right now.
Pipeline by stage
Where these companies sit on the ladder from a first grant to an approved product. Derived from evidence in public filings, never inferred past it.
- Grant-only557
- Formed3
- Preclinical0
- IND-enabling0
- Phase I20
- Phase II59
- Phase III34
- Filed/Approved7
Highest momentum in rare disease
Not included in your seat
Rare disease is outside your seat
The counts above are public. The ranked companies, their momentum, and their dossiers in Rare disease follow your seat. The free tier covers oncology; a Fund or Feed seat covers every area, and an Analyst seat can be switched to rare disease from your account.
Counts are public federal records; momentum is a recency-weighted score over public filing events, shown identically to every viewer. Informational only, not investment advice. All areas · Methodology